GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (XSWX:BION) » Definitions » Cyclically Adjusted Revenue per Share

BB Biotech AG (XSWX:BION) Cyclically Adjusted Revenue per Share : CHF6.03 (As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is BB Biotech AG Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

BB Biotech AG's adjusted revenue per share for the three months ended in Dec. 2023 was CHF2.027. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is CHF6.03 for the trailing ten years ended in Dec. 2023.

During the past 12 months, BB Biotech AG's average Cyclically Adjusted Revenue Growth Rate was -4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-04-30), BB Biotech AG's current stock price is CHF41.35. BB Biotech AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was CHF6.03. BB Biotech AG's Cyclically Adjusted PS Ratio of today is 6.86.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BB Biotech AG was 7.32. The lowest was 4.88. And the median was 6.56.


BB Biotech AG Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for BB Biotech AG's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG Cyclically Adjusted Revenue per Share Chart

BB Biotech AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 8.16 6.03

BB Biotech AG Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Dec17 Dec18 Dec19 Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.16 6.85 5.34 5.73 6.03

Competitive Comparison of BB Biotech AG's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, BB Biotech AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BB Biotech AG's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BB Biotech AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BB Biotech AG's Cyclically Adjusted PS Ratio falls into.



BB Biotech AG Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BB Biotech AG's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=2.027/106.4611*106.4611
=2.027

Current CPI (Dec. 2023) = 106.4611.

BB Biotech AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201106 0.000 102.678 0.000
201109 -1.393 101.811 -1.457
201112 1.674 101.408 1.757
201203 3.120 101.826 3.262
201206 2.238 101.596 2.345
201209 13.530 101.392 14.206
201212 -2.298 100.968 -2.423
201303 6.355 101.221 6.684
201306 11.793 101.466 12.374
201309 6.070 101.336 6.377
201312 1.800 101.036 1.897
201403 1.181 101.224 1.242
201406 3.555 101.517 3.728
201409 8.646 101.247 9.091
201412 12.909 100.704 13.647
201503 6.791 100.339 7.205
201506 6.190 100.464 6.560
201509 -10.123 99.785 -10.800
201512 9.193 99.386 9.847
201603 -21.715 99.475 -23.240
201606 0.802 100.088 0.853
201609 7.325 99.604 7.829
201612 -0.411 99.380 -0.440
201703 6.802 100.040 7.239
201706 2.045 100.285 2.171
201712 0.000 100.213 0.000
201812 0.000 100.906 0.000
201912 0.000 101.063 0.000
202012 0.000 100.241 0.000
202103 4.028 100.800 4.254
202106 2.585 101.352 2.715
202112 0.000 101.776 0.000
202203 -5.397 103.205 -5.567
202206 -4.039 104.783 -4.104
202209 4.019 104.835 4.081
202212 -0.612 104.666 -0.622
202303 -4.598 106.245 -4.607
202306 -0.083 106.576 -0.083
202309 -0.749 106.570 -0.748
202312 2.027 106.461 2.027

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


BB Biotech AG  (XSWX:BION) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

BB Biotech AG's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=41.35/6.03
=6.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BB Biotech AG was 7.32. The lowest was 4.88. And the median was 6.56.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


BB Biotech AG Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of BB Biotech AG's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BB Biotech AG (XSWX:BION) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (XSWX:BION) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.
Executives
Prof. Dr. Mads Krogsgaard Thomsen Supervisory Board

BB Biotech AG (XSWX:BION) Headlines

No Headlines